The efficacy of anti-IL-4/13 receptor monoclonal antibody on chronic prurigo

JRCT ID: jRCTs031200073

Registered date:21/07/2020

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: chronic prurigo
• Date of first enrollment: 21/07/2020
• Target sample size: 4
• Study type: Interventional
• Intervention(s): Treatment

Outcome(s)

• Primary Outcome: skin symptom
• Secondary Outcome: itch, blood examination

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1) a patient with chronic prurigo
2) a patient who was not improved by oral anti-histamine drug and topical steroid
3) a patient at age 20 or over
4) a patient who fully understand and agree to join this clinical study
5) outpatient

Exclude criteria

1) a patient orally administrated immune suppressants or high-dose steroid within three months
2) a patient who undergo UV photo therapy
3) a patinet who was treated with anti-IgE antibody within four months
4) a patient suffering from severe visceral diseases, autoimmune diseases, blood dosorders, and mental disorders
5) a patient who is pregnant or breast-feed
6) a patinet who is infected with parasite
7) a patient who is sensitive to this medication
6) a patient judged inadequate to this study

Related Information

• Primary Sponsor: Tsuyoshi Namiki
• Source(s) of Monetary Support: Japan Society for the Promotion of Science